SST2R and SST2R mRNA expression in rats with pancreatic cancer and the effect of octreotide
Qiu Faz
2002
Citations
1
Citations
Quality indicators
Journal
Chinese Journal of Pancreatology
Semantic Scholar
Key Takeaway Key Takeaway: Octreotide can decrease the expression of SST2R protein and mRNA in pancreatic cancer tissue, potentially due to low response of somatostatin analogues in pancreatic cancer.
Abstract
Objective To observe the effect of somatostatin analogues (octreotide) on the expression of protein and mRNA of somatostatin receptor-2(SST2R) in Sprauge Dawley (SD) rats with pancreatic cancer. Methods The rats pancreatic cancer was induced with dimethylbenzanthracine (DMBA). Fifty rats were divided into 4 groups: pancreatic cancer group (group A, rats with pancreatic cancer treated with saline), somatostatin analogues (octreotide, Sandostadin) group (group B, rats with pancreatic cancer treated with Sandostadin), negative control group (group C, rats given DMBA but no pancreatic cancer found), and normal control group (group D). In group A and B, the rats were treated with saline and octeotide (subcutaneous injection, 100 fig, qid) respectively, the protein and mRNA of SST2R in pancreatic cancer tissue were detected by radioimmunoassay or reverse transcription PCR (RT-PCR) 3, 7 and 14 days after treatment. Results The expression of SST2R protein and mRNA decreased significantly in group A and B, especially in group B (P0.05, vs group C and D). In group B, the expression of SST2R protein and mRNA also decreased significantly after the rats were treated with octreotide (P0.05, vs pretreatment or group A), but there was no statistic difference 3,7 and 14 days after the octreotide therapy in group B. Conclusions The SST2R protein and mRNA decreased significantly in rat pancreatic cancer tissue. Octreotide can decrease the expression, possibly because of low response of somatostatin analogues in pancreatic cancer.